venBio Partners LLC
13F Reported Value
ⓘ$280.6M
Holdings
6
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
venBio Partners LLC disclosed 6 positions worth $280.6M in its Form 13F-HR for Q1 2026, led by $PHVS (Pharvaris N.V.) at 46.7% of the equity portfolio, followed by $ALMS and $ALXO. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from venBio Partners LLC’s Form 13F-HR filing with the SEC under CIK 1776382.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$131.1M4,639,304 sh - 9.2#2,817
Quality
$99.8M4,528,408 sh - —
Quality
$25.8M12,884,638 sh - 75.3
Quality
$13.7M489,194 sh - 3.6
Quality
$6.8M337,697 sh - —
Quality
$3.4M531,337 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Pharvaris N.V.$PHVS | — | $131.1M | 4,639,304 |
 ALUMIS INC.$ALMS | 9.2#2,817 | $99.8M | 4,528,408 |
 ALX ONCOLOGY HOLDINGS INC$ALXO | — | $25.8M | 12,884,638 |
 Harmony Biosciences Holdings, Inc.$HRMY | 75.3 | $13.7M | 489,194 |
 Lyell Immunopharma, Inc.$LYEL | 3.6 | $6.8M | 337,697 |
 Artiva Biotherapeutics, Inc.$ARTV | — | $3.4M | 531,337 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of venBio Partners LLC's 6 positions.
Showing top 6 of 6 holdings.
Sector Allocation
Healthcare
$280.6M
Full Holdings — venBio Partners LLC (Q1 2026)
All 6 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PHVS | Pharvaris N.V. | $131.1M | 46.7% | +0% | — |
| 2 | $ALMS | ALUMIS INC. | $99.8M | 35.6% | -2% | 9.2 |
| 3 | $ALXO | ALX ONCOLOGY HOLDINGS INC | $25.8M | 9.2% | +33% | — |
| 4 | $HRMY | Harmony Biosciences Holdings, Inc. | $13.7M | 4.9% | +0% | 75.3 |
| 5 | $LYEL | Lyell Immunopharma, Inc. | $6.8M | 2.4% | +0% | 3.6 |
| 6 | $ARTV | Artiva Biotherapeutics, Inc. | $3.4M | 1.2% | -18% | — |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for venBio Partners LLC including:
Track venBio Partners LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for venBio Partners LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: venBio Partners LLC
13F Pro is an AI hedge fund tracker and stock research platform. For venBio Partners LLC (SEC CIK: 1776382), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in venBio Partners LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.